Progenerative Medical, Inc., a San Antonio-based-based company that develops and commercializes negative pressure therapies for the spine and general orthopedics, closed a $1.5m seed funding round.
The round was led by a group of undisclosed investors.
The company intends to use the funds to complete development of reduced pressure therapies for the spine and general orthopedics and initiate clinical evaluation of its first product, Regenn™ Therapy.
Founded in 2015 and James Poser, Ph.D., CEO and co-founder, Progenerative Medical is a clinical-ready medical device company developing Negative Pressure Therapy for spinal and orthopedic indications. In 2016, Progenerative entered into a technology licensing agreement with KCI for the exclusive, worldwide rights to KCI’s extensive intellectual property and preclinical product development portfolio for application of reduced pressure therapy in spine and orthopedic indications.
Regenn™ Therapy will initially be applied in spinal fusion procedures.